Introduction
Sensitivity to insulin-mediated glucose disposal varies widely in the population at large [1•]. When insulin-resistant individuals cannot maintain the degree of hyperinsulinemia needed to overcome the resistance, type 2 diabetes develops [2,3••] . However, even when insulin-resistant individuals secrete enough insulin to remain nondiabetic, they are at increased risk of developing a cluster of related abnormalities that lead to a variety of clinical syndromes. For example, in addition to type 2 diabetes, insulin-resistant individuals are more likely to develop cardiovascular disease (CVD), essential hypertension, polycystic ovary syndrome (PCOS), nonalcoholic fatty liver disease, and certain forms of cancer, and the list continues to expand. The National Cholesterol Education Panel (NCEP) has recognized the importance of insulin resistance as increasing CVD risk in nondiabetic individuals, and the Adult Treatment Panel III (ATP III) [4••] has published the criteria seen in Table 1 for making the diagnosis of what they refer to as the "Metabolic Syndrome." Although the report of the ATP III has the virtue of emphasizing the importance of insulin resistance and its consequences as increasing CVD risk, it is possible to question the specific formulation they have outlined. In the remainder of this article, some major concerns with the ATP III are expressed and a somewhat different approach to the problem is described.
A Rose by Any Other Name
Approximately 15 years ago, it was pointed out that insulin resistance and compensatory hyperinsulinemia in nondiabetic individuals were associated with a cluster of related abnormalities, including some degree of glucose intolerance, a high plasma triglyceride (TG) and a low high-density lipoprotein (HDL) cholesterol concentration, and essential hypertension [2] . Furthermore, it was pointed out that this cluster of related abnormalities associated with insulin resistance represented an important, but not well recognized, clinical syndrome (Syndrome X). Since the introduction of the notion of Syndrome X, the abnormalities associated with insulin resistance/compensatory hyperinsulinemia have grown almost as fast as the names that have been used to describe the phenomenon. Table 2 presents a summary of the abnormalities that occur with greater prevalence in insulin-resistant/hyperinsulinemic individuals, and Table 3 lists the clinical syndromes that are more likely to result as a consequence of these changes [5-27,28•,29-32] . Although CVD risk is certainly a major adverse consequence of insulin resistance, it is obviously not the only one. In light of the information in Tables 2 and 3 , there is some question as to the appropriateness of a designation such as the "Metabolic Syndrome" to adequately describe the clinical consequences likely to occur in insulin-resistant individuals. An alternative term, the "Insulin Resistance Syndrome," seems to more appropriately indicate that a defect in insulinmediated glucose disposal, and the response to this abnormality, increases the likelihood that an individual will display the abnormalities summarized in Table 2 and develop the clinical syndromes listed in Table 3 . The Metabolic Syndrome, as outlined in Table 1 , provides a list Insulin-mediated glucose disposal varies widely in apparently healthy human beings. When insulin-resistant individuals cannot secrete enough insulin to overcome this defect, type 2 diabetes occurs. However, the ability of hyperinsulinemia to prevent gross decompensation of glucose tolerance is a mixed blessing, and insulin-resistant/hyperinsulinemic individuals are more likely to be somewhat glucose intolerant, hypertensive, and have a high plasma triglyceride and low high-density lipoprotein cholesterol concentration. These changes increase the risk of cardiovascular disease, and in 1988 these relationships were explicitly addressed and designated as comprising a Syndrome X. The fact that insulin resistance and its consequences are important cardiovascular risk factors has become widely recognized, and the importance of this syndrome was acknowledged in the report of the Adult Treatment Panel III. There has been a rapid increase in the abnormalities associated with insulin resistance/compensatory hyperinsulinemia in the 15 years since the notion of Syndrome X was introduced, and there are now almost as many components as there are names that have been given to this cluster of abnormalities. Because there is a large body of evidence that the basic abnormality leading to all of these changes is resistance to insulin-mediated glucose disposal, it seems reasonable to suggest that the cluster of abnormalities related to the defect in insulin action be designated as the Insulin Resistance Syndrome.
of clinical findings that tend to cluster within an individual without implying any mechanistic explanation for why this happens. In contrast, the Insulin Resistance Syndrome offers a clear statement of the presumed pathogenesis of the syndrome, is based on evidence that insulin resistance and compensatory hyperinsulinemia significantly increase the likelihood of an individual developing the abnormalities and clinical syndromes shown in Tables 2 and 3 , and provides a broad umbrella under which all of the clinical syndromes related to insulin resistance/compensatory hyperinsulinemia can be gathered.
Differentiation Between the Insulin Resistance Syndrome and Type 2 Diabetes
Although the majority of insulin-resistant/hyperinsulinemic individuals do not become frankly hyperglycemic, they are at increased risk of developing type 2 diabetes. However, they are even at greater risk of developing CVD, and CVD is clearly the major cause of morbidity and mortality in patients with type 2 diabetes [33] . Because the vast majority of patients with type 2 diabetes are also insulin resistant [2,3••], it could be argued that the differentiation between the Insulin Resistance Syndrome and type 2 diabetes is inappropriate. However, the diagnosis of type 2 diabetes is relatively straightforward and based primarily upon the degree of hyperglycemia that increases risk of diabetic microangiopathy [34] . It is not as simple to identify insulinresistant individuals who do not have diabetes, and are, therefore, not at risk of developing the microangiopathic consequences associated with this diagnosis but are at increased CVD risk. The decision to differentiate between the two clinical syndromes is not to deny their many similarities, but only to provide a conceptual framework that recognizes the clinical importance of insulin resistance and compensatory hyperinsulinemia in the absence of frank hyperglycemia.
Obesity and the Insulin Resistance Syndrome
Descriptions of the Insulin Resistance Syndrome often include obesity, or abdominal obesity as in the case of the ATP III, as an integral feature of the syndrome. An alternative view is to consider obesity as a lifestyle variable that, along with physical inactivity, has an adverse effect on insulin-mediated glucose disposal [35-38,39••,40•] , thereby increasing the chances that the abnormalities and clinical syndromes associated with insulin resistance/ compensatory hyperinsulinemia will develop. The decision to view obesity in this latter manner is based upon the following considerations. Obesity is not a consequence of insulin resistance/hyperinsulinemia, but a physiologic variable that decreases insulin-mediated glucose disposal. [38,39••,40•] . For clarity of a pathophysiologic understanding of the Insulin Resistance Syndrome, it is important that obesity be viewed as contributing to the insulin resistance/hyperinsulinemia, rather than being a consequence of the defect in insulin action. This distinction is not meant to minimize the important role that the current epidemic of obesity plays in increasing the incidence of both type 2 diabetes and the Insulin Resistance Syndrome.
Secondly, it is proposed that body mass index (BMI), rather than abdominal circumference as suggested by the ATP III (Table 1) , be used to identify individuals at increased risk of having the Insulin Resistance Syndrome. 
